Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diagnostics/radiopharma sales decline at Schering AG:

This article was originally published in Clinica

Executive Summary

Declines in sales of X-ray contrast media and radiopharmaceuticals led to a 3% fall in net sales at Schering AG's diagnostics and radiopharmaceuticals business in 2002. Total divisional revenues of E1,406m ($1,525m) included E327m from MRI contrast agents (+2%) and E264m from contrast agent application technologies (+9%), but X-ray contrast media fell by 9% to E654m and there was a 4% decrease in radiopharmaceutical sales to E146m. The company was hit by negative price pressures and exchange rate effects.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel